China News Service, September 7th. On the 7th, Zheng Zhongwei, the leader of the vaccine research team of the scientific research team and director of the Science and Technology Development Center of the National Health Commission, said on the 7th that my country’s deployment of new coronavirus vaccines develops all vaccines for 5 technical routes. Achieved full coverage of clinical trials.
Data map: Sinopharm China Bio-New Crown Vaccine on the sub-packaging line.
Photo courtesy of Sinopharm Group
On the 7th, the State Council's Joint Prevention and Control Mechanism held a press conference on furthering the situation regarding epidemic prevention and control and vaccination.
A reporter asked at the meeting: As early as the beginning of last year, my country had deployed five technical routes for the development of new coronavirus vaccines. What new progress is there now?
In this regard, Zheng Zhongwei pointed out that my country has laid out 5 technical routes from the beginning of the outbreak to promote the research and development of new coronavirus vaccines, including inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, attenuated influenza virus vector vaccines and nucleic acid vaccines. , The main purpose is to ensure the success rate.
"Here I can tell you a clear message. So far, all the vaccines of our 5 technical routes have achieved full coverage of clinical trials." Zheng Zhongwei said, of which 3 inactivated vaccines have been attached by the State Food and Drug Administration. For the conditional marketing approval, 2 models were approved for emergency use by the State Food and Drug Administration.
One of the recombinant protein vaccines has been approved by the State Food and Drug Administration for emergency use. Currently, three are in phase III clinical trials, and five are in phase I and II clinical trials.
One adenovirus vector vaccine has been approved by the State Food and Drug Administration for conditional marketing, and three other vaccines are undergoing phase I and II clinical trials.
The attenuated influenza virus vector vaccine is undergoing phase II clinical trials, and preparations for overseas phase III clinical trials have also begun.
Nucleic acid vaccines my country has one mRNA vaccine and one DNA vaccine. Recently, they have obtained approvals for phase III clinical trials abroad, and it is estimated that phase III clinical trials will be carried out overseas recently.